The acquisition will complement Genpact’s portfolio of services in the Life Sciences vertical and add significant consulting, outsourcing and operations capabilities. With an ever-changing regulatory and commercial environment, the life sciences industry continues to face new challenges that require them to rely increasingly on experienced providers. It also significantly expands Genpact’s capabilities in supporting the life sciences research and development functions, including regulatory strategy, filing submissions, complex compliance services and the management of post-licensing activities.
Pharmalink’s specialised domain expertise, speed, responsiveness and ability to scalehave made it a leading provider for sustainable outsourcing of regulatory affairs services. Their clients include nearly all of the twenty largest global life sciences companies.Their specialized expertise includes the end-to-end range of regulatory services including strategy, chemistry manufacturing & controls (CMC), regulatory operations and publishing &technology services.
“This acquisition fits in exactly with our strategy to invest in solutions in specific growth areas in specific verticals such as Life Sciences,” said NV ‘Tiger’ Tyagarajan, President and CEO, Genpact. “In an industry that’s undergoing intense transformation, adding Pharmalink’s combination of talent, process expertise and domain knowledge to Genpact’s portfolio will allow us to better serve our life sciences clients.”
“Genpact will bring the global scale, process excellence, analytical insights and technology needed to further enhance our outsourcing services offering demanded by the market,”said Peter Griffin, Chairman, Pharmalink Consulting. “This combination will allow us todeliver more end-to-end regulatory affairs solutions based on Genpact’s proprietary Smart Enterprise Processes SEPSM methodology.”
Gary Charbonneau, Vice President of Global Regulatory Affairs at Allergan adds, “The combination of Genpact and Pharmalink is very exciting not just for me as a client, but for the industry at large. To have the deep experience and reputation of Pharmalink within the Regulatory Affairs arena allied to the scale and process excellence of Genpact is a compelling proposition.”
As part of the transaction, Pharmalink’s employees based in the US, the UK, India, Ireland and Puerto Rico will become part of Genpact’s Life Sciences vertical.
Genpact Limited (NYSE: G) is a global leader in transforming and running business processes and operations, including those that are complex and industry-specific. Our mission is to help clients become more competitive by making their enterprises more intelligent through becoming more adaptive, innovative, globally effective and connected to their own clients. Genpact stands for Generating Impact – visible in tighter cost management as well as better management of risk, regulations and growth for hundreds of long-term clients including more than 100 of the Fortune Global 500. Our approach is distinctive – we offer an unbiased, agile combination of smarter processes, crystallized in our Smart Enterprise Processes (SEPSM) proprietary framework, along with analytics and technology, which limits upfront investments and enhances future adaptability. We have global critical mass – 64,000+ employees in 24 countries with key management and corporate offices in New York City – while remaining flexible and collaborative, and a management team that drives client partnerships personally. Our history is unique – behind our single-minded passion for process and operational excellence is the Lean and Six Sigma heritage of a former General Electric division that has served GE businesses for more than 15 years. For more information, visit www.genpact.com. Follow Genpact on Twitter (http://twitter.com/#!/